Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.1K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.1K
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.8K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.8K
Therapeutic Index01:13

Therapeutic Index

6.8K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.8K
Therapeutic Communication01:30

Therapeutic Communication

8.0K
Communication is a lifelong learning process. Through therapeutic communication, nurses can collect relevant assessment data, provide education and counseling, and interact during nursing interventions. Sending and receiving messages occur through verbal and nonverbal communication techniques and can happen separately or simultaneously.
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
8.0K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.5K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.5K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.9K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nephroureterectomy for upper tract urothelial carcinoma recurrence in bladder cancer patients treated with radical cystectomy: a multicentric propensity score matched analysis on predictors, practice patterns and survival outcomes.

World journal of urology·2026
Same author

Limited Incremental Diagnostic Value of Perilesional and Systematic Biopsies in PI-RADS 4-5 Lesions: A Retrospective Single-Center Study.

Cancers·2026
Same author

Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates.

Prostate cancer and prostatic diseases·2026
Same author

A novel approach to endophytic renal mass: Percutaneous indocyanine green injection for fluorescence-guided robot-assisted renal Tumorectomy.

Urology case reports·2026
Same author

Accuracy, readability, and understandability of European Association of Urology guidelines bot for Sexual and Reproductive Health Guidelines.

The journal of sexual medicine·2026
Same author

Accuracy, readability, and understandability of EAU Guidelines Bot for urinary infections guidelines.

Minerva urology and nephrology·2026

Related Experiment Video

Updated: Jan 31, 2026

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.5K

[5ARI and PSA: therapeutic aspects].

Alessandro Sciarra1

  • 1Coordinatore Prostate Unit, Dipartimento Urologia, Policlinico Umberto I, Università Sapienza, Roma - Italy.

Urologia
|April 19, 2014
PubMed
Summary
This summary is machine-generated.

5-alpha reductase inhibitors help manage prostate-specific antigen (PSA) levels in benign prostatic hyperplasia (BPH), reducing unnecessary prostate biopsies. Alpha-blockers do not offer the same benefit, potentially increasing biopsy risks.

More Related Videos

Technical Aspects of the Mouse Aortocaval Fistula
06:12

Technical Aspects of the Mouse Aortocaval Fistula

Published on: July 11, 2013

17.5K
Development of New Therapeutic Applications Using Microfluidics
08:56

Development of New Therapeutic Applications Using Microfluidics

Published on: October 1, 2007

5.7K

Related Experiment Videos

Last Updated: Jan 31, 2026

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.5K
Technical Aspects of the Mouse Aortocaval Fistula
06:12

Technical Aspects of the Mouse Aortocaval Fistula

Published on: July 11, 2013

17.5K
Development of New Therapeutic Applications Using Microfluidics
08:56

Development of New Therapeutic Applications Using Microfluidics

Published on: October 1, 2007

5.7K

Area of Science:

  • Urology
  • Oncology
  • Pharmacology

Background:

  • Prostate-specific antigen (PSA) levels can be elevated due to prostate cancer, benign prostatic hyperplasia (BPH), or inflammation.
  • Distinguishing PSA elevations caused by BPH from those of prostate cancer is crucial for appropriate patient management.

Purpose of the Study:

  • To evaluate the impact of different medications on PSA levels in patients with BPH.
  • To assess the risk of unnecessary prostate biopsies based on PSA trends and medication use.

Main Methods:

  • Analysis of PSA levels in patients with progressive BPH treated with 5-alpha reductase inhibitors versus alpha-blockers.
  • Correlation of PSA changes with the need for prostate biopsies.

Main Results:

  • 5-alpha reductase inhibitors led to PSA reduction and stabilization, decreasing the risk of unnecessary biopsies.
  • Monotherapy with alpha-blockers in progressing BPH with elevated PSA did not prevent PSA modifications related to benign disease, increasing biopsy risk.

Conclusions:

  • 5-alpha reductase inhibitors effectively manage PSA levels in BPH, aiding in the avoidance of unnecessary prostate cancer diagnostic procedures.
  • Alpha-blocker monotherapy may not adequately control PSA fluctuations in BPH, potentially leading to increased diagnostic uncertainty and biopsies.